×
Skip to content
ShareCafe

  • Home
  • Shares
  • Advice
  • Wealth
    • Wealth Home
    • Product Profiles
  • Property
  • Video
  • Contributors
  • Community
  • About us
  • Facebook
  • Twitter
  • YouTube
  • RSS
Main Menu
Nick Langley

Nick Langley

Managing Director, Co-Founder, Senior Portfolio Manager, RARE Infrastructure As a Managing Director, Co-Founder, Senior Portfolio Manager, Nick is a member of RARE’s Management and Investment Leadership Team and is responsible for the management of RARE’s Australian operations. As a member of the Investment Leadership Team, Nick is responsible for the governance and management of the investment team and the investment process. As a Senior Portfolio Manager, Nick is a member of the investment committees responsible for the investment performance across RARE’s Value, Income and Emerging Market strategies. Prior to founding RARE in 2006, Nick spent 11 years in the infrastructure sector including four years as a Principal of AMP Capital’s Infrastructure Funds Management team, where he was also the CFO of DUET, an ASX-listed investment trust with AUD 5 billion in electricity and gas assets. Nick also spent two years with UBS in New York and, prior to that, worked with ABN AMRO in Sydney to provide advice across various infrastructure sectors such as communications, multi-utilities and transport. Nick holds a Bachelor of Laws and a Bachelor of Commerce from the University of Auckland.

Funds / Markets / Property

Infrastructure Outlook: Greater Outlays to Boost Growth

December 15, 2020 - by Nick Langley

Encouraging developments on the vaccine front late in 2020 and advances in the world’s ability to manage infection rates while still working, learning and spending are positive signs for 2021, and we are constructive on the outlook for global listed infrastructure for several reasons.

Read More
Funds

The Push for Sustainable Infrastructure

October 9, 2020October 9, 2020 - by Nick Langley

The COVID-19 pandemic has meaningfully hit most countries in the world, bringing with it a toll on human lives and livelihoods. As governments move to mitigate the public health crisis and support economies through monetary and fiscal policy, many are asking if governments will stimulate their economies with investments in infrastructure.

Read More

Recently Added

  • Two Top Risks for 2021 and ETFs that May Benefit
  • Oil Consumption Predicted to Fall in 2021
  • BHP Riding High on Commodities Strength
  • AFIC Beats Broader Market with 15.2% Return for 2H20
  • Store Closures Hit API Bottom Line
  • Netflix Tops 200m Global Subscribers, Share Price Jumps
  • Evening Report: ASX 200 hits 11-month highs
  • Lunch Report: Technology, energy and industrial stocks lead ASX higher

Subscribe to ShareCafe

The daily resource for hands-on investors. Market insights and investment ideas delivered free to your inbox.

Copyright 2020 Informed Investor Pty Ltd ABN 42 162 871 589. All rights reserved.
No portion of this website maybe reproduced, copied or in any way released without written permission.
Share Cafe is a Corporate Authorised Representative (001283561) of PacReef Asset Management Pty Ltd who holds an Australian Financial Services Licence (Number: 488045)

Terms of Service | Financial Services Guide | Privacy Policy | Contact | Advertise

DOWNLOAD RESEARCH REPORT

And a Door Opens Wide

Antisense Therapeutics’ lead drug sits at the nexus of two areas of drug development that are starting to grow dramatically in importance. One relates to its mode of action and the other to the type of drug it is. Combine that with management who know the drug very well and strong results in a trial in a horrible disease afflicting children, and you have the basis for true value creation.

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the Tree.


DOWNLOAD RESEARCH REPORT

Fit for tough times; prepared for coal’s upswing

Terracom has counter-cyclically placed itself in a position to improve efficiency and margins plus pursue organic mine growth. Cashflows will further swell once currently depressed coal prices rebound. These assets appear undervalued compared to our Base Case $0.27/share NPV valuation of TER. TER has upside on management’s record of delivering new projects from currently controlled development assets and/or by opportunistically securing acquisitions.

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the Plane.

DOWNLOAD RESEARCH REPORT

A Laser-Like Focus on Adding Value

Since August 1st, Kazia Therapeutics has announced US Food & Drug Administration fast track status for one program & orphan drug and rare paediatric disease designation for another, while finishing the period by announcing a new trial for its cancer drug, paxalisib. Over the next nine months investors are likely to see six data readouts from five programs. How fast can a company go?

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the House.